FAQ'S
- For Potential Investors
- For Founders & Investee Companies
The Alanar One Health Fund is a Category II AIF, investing in unlisted businesses across pharmaceutical engineering, healthcare, biotechnology, and life-sciences infrastructure. We focus on sectors where complexity is unavoidable, regulatory risk is real, and long-term execution—not short-term momentum—creates durable value.
The fund targets ₹126 crore, with a ₹54 crore greenshoe. This allows us to remain selective while retaining flexibility to increase exposure where conviction is high and execution visibility is strong.
₹1 crore, with an initial drawdown of 20%. This structure ensures alignment with investors who are comfortable with patient capital and understand that value in these sectors compounds over time.
Our core focus is pharmaceutical engineering, with selective exposure to healthcare, biotechnology, pharmaceuticals, and emerging areas such as gene therapy andregenerative medicine—where technical depth and regulatory understanding matter.
Our primary focus is unlisted and pre-IPO opportunities. That said, we remain open to companies where the growth opportunity is clear, executable, and aligned with our long-term, system-driven approach.
Risk is addressed upfront through deep sector understanding, detailed diligence, and realistic assessment of regulatory and operating constraints. We also stay involved through key inflection points, where most long-term risk actually emerges.
We typically invest in growth-stage businesses—companies that have proven relevance but require disciplined capital and sound judgment to scale responsibly and sustainably.
26% for 15-20 Cr.
We make meaningful minority investments, with flexibility on structure and sizing. The focus is on alignment and impact, not rigid ticket brackets.
The ecosystem is not a value-add service—it’s an operating reality. It informs diligence, reduces execution risk, and supports portfolio companies with practical insight drawn from decades of real work.
We are actively involved when decisions carry long-term consequences and deliberately restrained when they don’t. Presence without interference is the goal.
Long enough for systems to mature and value to compound properly. We don’t optimise for early exits at the expense of durability or long-term outcomes.
We invest in engineering-led, system-driven businesses where execution quality, regulatory discipline, and operational depth matter more than narratives or short-term optics.
Typically growth stage. That said, we’ve never said no to a business with genuine potential, provided there is clarity of direction and willingness to build with discipline.
Yes. Founders continue to lead their businesses. Our role is to reinforce systems, improve decision-making, and support scale—not to replace leadership or vision.
We engage most during strategic decisions, regulatory transitions, and scale-up phases. Outside of that, we stay out of the way and let teams execute.
We believe growth is essential—every business exists to grow. We simply believe growth should be supported by systems that can sustain it, not forced ahead of readiness.
It means access to operating judgment, sector understanding, and an embedded ecosystem built over decades—activated selectively, only when it creates real leverage.
These environments are familiar ground. We invest with a clear understanding of regulatory pathways, compliance requirements, and realistic timelines from the outset.
That’s when we lean in the most—helping founders think through trade-offs, priorities, and structural decisions that shape long-term outcomes.
Founders looking for capital without accountability, acceleration without discipline, or a passive glide path to retirement are unlikely to find alignment with us.
